Biotechnology
HTPE Leads JYSSBIO to Close Series B+ Funding
HANGZHOU, China, Jan. 17, 2022 /PRNewswire/ -- Huatai International Private Equity Fund ("HTPE"), the Greater China focused private equity investment platform under Huatai Securities, is pleased to announce that it led the Series B+ financing ofZhejiang JYSS Bio-Engineering Co., Ltd. ("JYSSBIO" ...
2022-01-17 17:58
4807
The Philippines Has Approved ReCOV For Phase II/III Cinical Trial
* Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial * ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta * Rhecogen , a subsidiary focused on mRNA vaccines of th...
2022-01-17 16:57
3647
French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City
GUANGZHOU, ChinaJan. 15, 2022 /PRNewswire/ -- On the afternoon of January 14th, Mr. Sylvain FOURRIERE, Consul General ofFrance in Guangzhou, and officers from consulates general of 9 countries includingBritain, Canada and Switzerland visited China-Singapore Guangzhou Knowledge City andSingapore -...
2022-01-15 08:00
6704
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne
HANGZHOU and SHAOXING, China, Jan. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne. ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme whic...
2022-01-13 17:30
4679
Accuredit Therapeutics and N1 Life Form a Joint Venture Named 'Napoltec', Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical Translation
SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Accuredit Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Accuredit), an emerging company based on new generations of safe and highly targeted gene editing therapies, and N1 Life, a biotech company focused on developing cutting-edge drug de...
2022-01-13 13:33
4194
CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
* Sugemalimab has the potential to become the world's first immunotherapy to be approved for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) * The National Medical Products Administration (NMPA) of China has granted the Breakthrough Therapy Designati...
2022-01-13 08:05
7601
Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference
SEOUL, South Korea, Jan. 13, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthcare virtual Conference. Dr.Jong-Yoon Chun, CEO of Seegene...
2022-01-13 04:00
3687
Evolved by Nature Announces IDE Approval from the FDA to Initiate a Pivotal Clinical Trial for its first Activated Silk™ Dermal Filler
BOSTON, Jan. 12, 2022 /PRNewswire/ -- Biotechnology company Evolved by Nature announced today that sister company Silk Medical Aesthetics has received Investigational Device Exemption (IDE) approval from the FDA to initiate a pivotal clinical trial for its new dermal filler for the correction of ...
2022-01-12 21:00
3158
South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine
GAITHERSBURG, Md., Jan. 12, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, today...
2022-01-12 20:43
2992
Singapore biotech firm JN Medsys develops a PCR test kit that specifically detects for the Omicron variant with high accuracy
SINGAPORE, Jan. 12, 2022 /PRNewswire/ -- Singapore-based biotech firm, JN Medsys announces that it has developed a new PCR kit that detects for SARS-CoV-2 and identifies if the Omicron variant is present. It can be used on upper respiratory samples and the results can be available in just 1 hour....
2022-01-12 18:18
2286
Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCC
SUZHOU, China, Jan. 12, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the TST001 US P...
2022-01-12 15:15
3713
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease
* ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease * ABL301 uses ABL's Grabody-B platform technology to ef...
2022-01-12 07:59
4025
PostEra announces $260M multi-target strategic AI Lab collaboration with Pfizer
BOSTON, Jan. 11, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced the expansion of the company'sexisting strategic collaboration with Pfizer. The expanded multi-target research program will establish anAI Lab w...
2022-01-11 22:00
3937
SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study
BOSTON and LAUSANNE, Switzerland, Jan. 11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT0...
2022-01-11 20:27
2321
Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster
TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced thatPreprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of ...
2022-01-11 15:15
3163
MGI Aims to Boost its Market Share through Participation at Expo 2020 Dubai's Guangdong Week
DUBAI, UAE, Jan. 11, 2022 /PRNewswire/ -- Global life science innovator MGI Tech Co. Ltd. (MGI) is aiming to boost its market share in theMiddle East and Asia through participation at Guangdong Week, a dedicated event taking place at the world exhibition's China Pavilion fromJanuary 11-13. The ...
2022-01-11 14:00
2587
Pfizer Drives Cultural Change in Sustainable and Accessible Data with MicroStrategy
SINGAPORE, Jan. 11, 2022 /PRNewswire/ -- MicroStrategy
2022-01-11 09:30
3148
Cyclone Robotics Was Recognized as a "Strong Performer" by the "Gartner Peer Insights 'Voice of the Customer': Robotic Process Automation" Report
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Recently, the world's authoritative technology research and analysis organization Gartner published the report "Gartner Peer Insights 'Voice of the Customer': Robotic Process Automation". Cyclone Robotics was the featured highlight in the report and was nam...
2022-01-10 22:01
2831
JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, recently announced the appointments of Dr.Shaun Paul Cordoba as Chief Scientific Officer (...
2022-01-10 09:30
4367
CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China
TIANJIN, China, Jan. 9, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration ofChina ("NMPA") granted approval for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) ("MCV4", trade name: Menhycia™), ma...
2022-01-09 10:09
4636
Week's Top Stories
Most Reposted
DayOne Appoints Nicolas Aguzin to Board of Directors, Strengthening Global Governance and Capital Markets Expertise
[Picked up by 281 media titles]
2026-05-29 15:50Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Creality 3D Successfully Listed in Hong Kong
[Picked up by 271 media titles]
2026-05-29 11:21
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
[Picked up by 269 media titles]
2026-05-30 11:58
PHOTO & IMAGE SHANGHAI 2026 to Showcase AI Imaging, Content-Creation Technologies and Emerging Visual Trends This July
[Picked up by 269 media titles]
2026-05-29 17:36
Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
7838
AMTD's Successful Completion of Acquisition of The Ritz-Carlton, Perth, Valued at A$280 Million
2026-05-29 21:50
7331
Creality 3D Successfully Listed in Hong Kong
2026-05-29 11:21
6667
Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering
2026-05-29 22:00
6421